Patnaik MM - Search Results

1

Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis.

Tefferi A, Partain DK, Palmer JM, Slack JL, Roy V, Hogan WJ, Litzow ML, Ketterling RP, Patnaik MM. Tefferi A, et al. Among authors: patnaik mm. Am J Hematol. 2018 May;93(5):649-654. doi: 10.1002/ajh.25053. Epub 2018 Feb 24. Am J Hematol. 2018. PMID: 29388258 Free article.

2

FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.

Pardanani A, Ketterling RP, Li CY, Patnaik MM, Wolanskyj AP, Elliott MA, Camoriano JK, Butterfield JH, Dewald GW, Tefferi A. Pardanani A, et al. Among authors: patnaik mm. Leuk Res. 2006 Aug;30(8):965-70. doi: 10.1016/j.leukres.2005.11.011. Epub 2006 Jan 6. Leuk Res. 2006. PMID: 16406016

3

Eosinophilia: secondary, clonal and idiopathic.

Tefferi A, Patnaik MM, Pardanani A. Tefferi A, et al. Among authors: patnaik mm. Br J Haematol. 2006 Jun;133(5):468-92. doi: 10.1111/j.1365-2141.2006.06038.x. Br J Haematol. 2006. PMID: 16681635 Free article. Review.

4

Systemic mastocytosis: a concise clinical and laboratory review.

Patnaik MM, Rindos M, Kouides PA, Tefferi A, Pardanani A. Patnaik MM, et al. Arch Pathol Lab Med. 2007 May;131(5):784-91. doi: 10.5858/2007-131-784-SMACCA. Arch Pathol Lab Med. 2007. PMID: 17488167 Free article. Review.

5

Kit: molecule of interest for the diagnosis and treatment of mastocytosis and other neoplastic disorders.

Patnaik MM, Tefferi A, Pardanani A. Patnaik MM, et al. Curr Cancer Drug Targets. 2007 Aug;7(5):492-503. doi: 10.2174/156800907781386614. Curr Cancer Drug Targets. 2007. PMID: 17691909 Review.

6

The complete evaluation of erythrocytosis: congenital and acquired.

Patnaik MM, Tefferi A. Patnaik MM, et al. Leukemia. 2009 May;23(5):834-44. doi: 10.1038/leu.2009.54. Epub 2009 Mar 19. Leukemia. 2009. PMID: 19295544 Review.

7

Molecular diagnosis of myeloproliferative neoplasms.

Patnaik MM, Tefferi A. Patnaik MM, et al. Expert Rev Mol Diagn. 2009 Jul;9(5):481-92. doi: 10.1586/erm.09.29. Expert Rev Mol Diagn. 2009. PMID: 19580432 Review.

8

JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival.

Tefferi A, Lasho TL, Patnaik MM, Finke CM, Hussein K, Hogan WJ, Elliott MA, Litzow MR, Hanson CA, Pardanani A. Tefferi A, et al. Among authors: patnaik mm. Leukemia. 2010 Jan;24(1):105-9. doi: 10.1038/leu.2009.225. Epub 2009 Oct 22. Leukemia. 2010. PMID: 19847199

9

Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival.

Patnaik MM, Caramazza D, Gangat N, Hanson CA, Pardanani A, Tefferi A. Patnaik MM, et al. Eur J Haematol. 2010 Feb 1;84(2):105-8. doi: 10.1111/j.1600-0609.2009.01373.x. Epub 2009 Nov 6. Eur J Haematol. 2010. PMID: 19895568

10

Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution.

Patnaik MM, Gangat N, Knudson RA, Keefe JG, Hanson CA, Pardanani A, Ketterling RP, Tefferi A. Patnaik MM, et al. Am J Hematol. 2010 Apr;85(4):238-42. doi: 10.1002/ajh.21631. Am J Hematol. 2010. PMID: 20143402 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

446 results

Search Page

Filters